Market Place
Sourcing Support
First Shipment of Henlius Trastuzumab to U.S.
02 Dec 2024 //
PR NEWSWIRE
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
30 Nov 2024 //
BLOOMBERG
Celltrion`s Biologic Herzuma Receives Suppl Approval in US
14 Nov 2024 //
FDA
Mylan Gmbh`s Biologic Ogivri Receives Suppl Approval in US
13 Nov 2024 //
FDA
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu News
09 Nov 2024 //
PHARMAPHORUM
Govt asks manufacturers to cut price of 3 anti-cancer drugs
29 Oct 2024 //
ECONOMICTIMES
ENHERTU Granted Priority Review For HER2 Low Breast Cancer
30 Sep 2024 //
BUSINESSWIRE
Prestige`s Tuznue (trastuzumab) Receives Approval in Europe
19 Sep 2024 //
EMA
Accord BioPharma`s HERCESSI 420mg Receives FDA Approval for HER2 Cancers
18 Sep 2024 //
PR NEWSWIRE
KEYTRUDA Combo Improves OS In HER2+ Gastric Or GEJ Adenocarcinoma
14 Sep 2024 //
BUSINESSWIRE
ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases
13 Sep 2024 //
BUSINESSWIRE
Daiichi Sankyo Unveils New ADC Research in Multiple Cancers at WCLC and ESMO
04 Sep 2024 //
BUSINESSWIRE
Enliven Therapeutics Reports Q2 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Genentech`s Trastuzumab; Hyaluronidase-Oysk Receives Suppl Approval in US
18 Jun 2024 //
FDA
Genentech Biologic Trastuzumab Receives Suppl Approval in US
18 Jun 2024 //
FDA
Astra`s Enhertu breast cancer trial shows `unprecedented` results
03 Jun 2024 //
REUTERS
ENHERTU Shows 13.2 Month PFS In HER2-Low/Ultralow Metastatic Breast Cancer
02 Jun 2024 //
BUSINESSWIRE
Accord BioPharma’s HERCESSI secures FDA approval
30 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
AZ, Daiichi tout Enhertu win in earlier, broader HER2-low cancer
29 Apr 2024 //
FIERCE PHARMA
FDA Approves Accord`s HERCESSI™, Herceptin® Biosimilar
29 Apr 2024 //
PR NEWSWIRE
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
29 Apr 2024 //
BUSINESSWIRE
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
06 Apr 2024 //
REUTERS
Biocon Biologics partners with Sandoz Australia for Biosimilars
10 Feb 2024 //
INDIAN PHARMA POST
Sandoz`s Herwenda (trastuzumab) Receives Approval in Europe
23 Nov 2023 //
EMA
KEYTRUDA Plus Trastuzumab Improved Versus Trastuzumab and Chemotherapy in GEJ
20 Oct 2023 //
BUSINESSWIRE
Sandoz receives positive CHMP opinion for biosimilar trastuzumab
18 Sep 2023 //
GLOBENEWSWIRE
Glenmark Pharma slashes price of breast cancer drug Trastuzumab
15 Jun 2023 //
ECONOMIC TIMES
U.S. FDA Issues Complete Response Letter for Byondis` Trastuzumab Duocarmazine
16 May 2023 //
PR NEWSWIRE
Biocon Biologics facility gets EU GMP certification for Bevacizumab
29 Apr 2023 //
HEALTH ET
Seagen Announces FDA Accelerated Approval of TUKYSA with Trastuzumab
19 Jan 2023 //
BUSINESSWIRE
NPPA revises ceiling prices of 128 formulations
17 Jan 2023 //
ECONOMIC TIMES
INmune Bio, Inc. Reports Combination Therapy with INB03™
06 Dec 2022 //
GLOBENEWSWIRE
Prestige Submitted Pre-BLA Meeting Request to FDA for Herceptin Biosimilar
13 Oct 2022 //
BUSINESSWIRE
Roche receives FDA approval for first companion diagnostic to identify patients
04 Oct 2022 //
GLOBENEWSWIRE
Seagen to Highlight Research in Urothelial & Colorectal Cancers at ESMO Congress
07 Sep 2022 //
BUSINESSWIRE
Enhertu strikes again with a PhIII success in another breast cancer population
16 Aug 2022 //
ENDPTS
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
03 Aug 2022 //
BUSINESSWIRE
EMA Validates MAA for Trastuzumab Duocarmazine (SYD985) in HER2-Positive MBC
18 Jul 2022 //
PRNEWSWIRE
FDA Accepts Byondis` BLA for [Vic-] Trastuzumab Duocarmazine (SYD985)
12 Jul 2022 //
PRNEWSWIRE
Seagen Announces Results from Pivotal MOUNTAINEER Trial in TUKYSA
02 Jul 2022 //
BUSINESSWIRE
Roche launches antibody drug for breast cancer in India
13 May 2022 //
ECONOMIC TIMES
Chugai gets Japanese approval for Perjeta, Herceptin in HER-2 positive CC
29 Mar 2022 //
PHARMABIZ
NICE draft guidance recommends tucatinib for advanced breast cancer
25 Feb 2022 //
PHARMAFILE
FDA Grants ODD to Celularity`s NK Cell Therapy CYNK-101 in GI Cancers
15 Feb 2022 //
GLOBENEWSWIRE
Celularity Receives FTD from FDA for its NK Cell Therapy CYNK-101
18 Jan 2022 //
GLOBENEWSWIRE
Cadila Pharmaceuticals expands oncology portfolio, launches Tarzed
06 Jan 2022 //
EXPRESSPHARMA
Sandoz submits Marketing Authorizationfor proposed biosimilar trastuzumab to EMA
22 Dec 2021 //
GLOBENEWSWIRE
Sandoz submits BLA for proposed biosimilar trastuzumab to US FDA
22 Dec 2021 //
PHARMABIZ
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab
20 Dec 2021 //
GLOBENEWSWIRE
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine
10 Dec 2021 //
GLOBENEWSWIRE
ENHERTU Additional Analyses Reinforce Ground-breaking Efficacy in Breast Cancer
09 Dec 2021 //
BUSINESSWIRE
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA
08 Dec 2021 //
BUSINESSWIRE
Prestige, Dr. Reddy’s partner to commercialize trastuzumab biosimilar
08 Dec 2021 //
BUSINESSWIRE
Henlius` 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by NMPA
03 Dec 2021 //
ASIAONE
Chugai’s Herceptin gets Japanese approval for salivary gland cancer
26 Nov 2021 //
PHARMABIZ
Actinium Presents First Ever Data with a CD47 Immunotherapy in Comb a HER2(SITC)
13 Nov 2021 //
PRNEWSWIRE
NICE does not recommend tucatinib in new draft guidance
26 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW
Zymeworks to Present HERIZON-GEA-01 Pivotal Trial Design and more...
26 Oct 2021 //
BUSINESSWIRE
